KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).

Sandip M Prasad, William C Huang, Neal D Shore, Brian Hu, Marc Bjurlin, Gordon Brown, Pencho Genov, Dimitar Shishkov, Alexandre Khuskivadze, Tosho Ganev, Dobri Marchev, Igor Orlov, Evgeny Kopyltsov, Vadim Zubarev, Alexander Nosov, Dmitrii Komlev, Brent Burger, Sunil Raju, Andrew Meads, Mark Schoenberg

J Urol 210(4) 619-629

PMID37548555
PMCIDPMC12721658
DOI10.1097/JU.0000000000003645
发表日期2023-08-07
入排依据:The record describes a randomized Phase III trial with a time-to-event primary endpoint (disease-free survival). However, the intervention (UGN-102) is a drug-containing gel for local chemoablation, and the study is framed as a comparison of a chemoablation technique versus a surgical procedure (TURBT). The adjudication rules require a 'drug-containing intervention,' but the context and primary analysis emphasize the procedural/ablation aspect, making the drug component not the clear, primary therapeutic modality under test. Therefore, it does not meet the strict criterion for a drug intervention as defined for this cohort.
摘要

摘要

PURPOSE: Low-grade intermediate-risk nonmuscle-invasive bladder cancer is a chronic illness commonly treated by repetitive transurethral resection of bladder tumor. We compared the efficacy and safety of intravesical chemoablation with UGN-102 (a reverse thermal gel containing mitomycin), with or without subsequent transurethral resection of bladder tumor, to transurethral resection of bladder tumor alone in patients with low-grade intermediate-risk nonmuscle-invasive bladder cancer. MATERIALS AND METHODS: This prospective, randomized, phase 3 trial recruited patients with new or recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer to receive initial treatment with either UGN-102 once weekly for 6 weeks or transurethral resection of bladder tumor. Patients were followed quarterly by endoscopy, cytology, and for-cause biopsy. The primary end point was disease-free survival. All patients were followed for adverse events. RESULTS: Trial enrollment was halted by the sponsor to pursue an alternative development strategy after 282 of a planned 632 patients were randomized to UGN-102 ± subsequent transurethral resection of bladder tumor (n=142) or transurethral resection of bladder tumor monotherapy (n=140), rendering the trial underpowered to perform hypothesis testing. Patients were predominantly male and ≥65 years of age. Tumor-free complete response 3 months after initial treatment was achieved by 92 patients (65%) who received UGN-102 and 89 patients (64%) treated by transurethral resection of bladder tumor. The estimated probability of disease-free survival 15 months after randomization was 72% for UGN-102 ± transurethral resection of bladder tumor and 50% for transurethral resection of bladder tumor (hazard ratio 0.45). The most common adverse events (incidence ≥10%) in the UGN-102 group were dysuria, micturition urgency, nocturia, and pollakiuria. CONCLUSIONS: Primary, nonsurgical chemoablation with UGN-102 for the management of low-grade intermediate-risk nonmuscle-invasive bladder cancer offers a potential therapeutic alternative to immediate transurethral resection of bladder tumor monotherapy and warrants further investigation.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。